Tags

Type your tag names separated by a space and hit enter

Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease.
Dis Nerv Syst. 1977 Aug; 38(8):605-8.DN

Abstract

Forty-two patients with Parkinson's disease were given amantadine HC1 (Symmetrel) and placebo in an 18 week double-blind cross-over study to determine if amantadine provided additional benefit when combined with levodopa and carbidopa (Sinemet). Analysis of our results showed that amantadine effected a 92% improvement over baseline in symptom scores and a 95% improvement over baseline in activity impairment scores, compared with corresponding values of 4% and 18% for placebo. The difference between amantadine and placebo was statistically significant. Except for one case of mild livedo reticularis and two of blurred vision in the amantadine group, side effects were generally similar for amantadine and placebo in type and frequency. This study provides new evidence of the importance of combinations of antiparkinson drugs to achieve maximum therapeutic benefit.

Authors

No affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

328244

Citation

Savery, F. "Amantadine and a Fixed Combination of Levodopa and Carbidopa in the Treatment of Parkinson's Disease." Diseases of the Nervous System, vol. 38, no. 8, 1977, pp. 605-8.
Savery F. Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease. Dis Nerv Syst. 1977;38(8):605-8.
Savery, F. (1977). Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease. Diseases of the Nervous System, 38(8), 605-8.
Savery F. Amantadine and a Fixed Combination of Levodopa and Carbidopa in the Treatment of Parkinson's Disease. Dis Nerv Syst. 1977;38(8):605-8. PubMed PMID: 328244.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease. A1 - Savery,F, PY - 1977/8/1/pubmed PY - 1977/8/1/medline PY - 1977/8/1/entrez SP - 605 EP - 8 JF - Diseases of the nervous system JO - Dis Nerv Syst VL - 38 IS - 8 N2 - Forty-two patients with Parkinson's disease were given amantadine HC1 (Symmetrel) and placebo in an 18 week double-blind cross-over study to determine if amantadine provided additional benefit when combined with levodopa and carbidopa (Sinemet). Analysis of our results showed that amantadine effected a 92% improvement over baseline in symptom scores and a 95% improvement over baseline in activity impairment scores, compared with corresponding values of 4% and 18% for placebo. The difference between amantadine and placebo was statistically significant. Except for one case of mild livedo reticularis and two of blurred vision in the amantadine group, side effects were generally similar for amantadine and placebo in type and frequency. This study provides new evidence of the importance of combinations of antiparkinson drugs to achieve maximum therapeutic benefit. SN - 0012-3714 UR - https://www.unboundmedicine.com/medline/citation/328244/Amantadine_and_a_fixed_combination_of_levodopa_and_carbidopa_in_the_treatment_of_Parkinson's_disease_ L2 - https://medlineplus.gov/parkinsonsdisease.html DB - PRIME DP - Unbound Medicine ER -